Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-11-04
1998-05-12
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540521, 540522, C07D47104, A61K 3155
Patent
active
057505217
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
Enkephalinase or, more specifically, endopeptidase-24.11, is a mammalian ectoenzyme which is involved in the metabolic degradation of certain circulating regulatory peptides. This enzyme, which is a Zn.sup.+2 -metallopeptidase, exerts its effect by cleaving the extracellular peptides at the amino group of hydrophobic residues and thus inactivates the peptides as regulatory messengers.
Enkephalinase is involved in the metabolic degradation of a variety of circulating regulatory peptides including endorphins, such as .beta.-endorphin and the enkephalins, atrial natriuretic peptide (ANP), and other circulating regulatory peptides.
Endorphins are naturally-occurring polypeptides which bind to opiate receptors in various areas of the brain and thereby provide an analgesic effect by raising the pain threshold. Endorphins occur in various forms including .alpha.-endorphin, .beta.-endorphin, .gamma.-endorphin as well as the enkephalins. The enkephalins, i.e., Met-enkephalin and Leu-enkephalin, are pentapeptides which occur in nerve endings of brain tissue, spinal cord and the gastrointestinal tract.
Like the other endorphins, the enkephalins provide an analgesic effect by binding to the opiate receptors in the brain. By inhibiting enkephalinase, the metabolic degradation of the naturally-occurring endorphins and enkephalins are inhibited, thereby providing a potent endorphin- or enkephalin-mediated analgesic effect. Inhibition of enkephalinase would therefore be useful in a patient suffering from acute or chronic pain. Inhibition of enkephalinase would also be useful in providing an antidepressant effect and in providing a reduction in severity of withdrawal symptoms associated with termination of opiate or morphine administration. In addition, inhibition of enkephalinase would also be useful in the treatment of irritable bowel syndrome.
ANP refers to a family of naturally-occurring peptides which are involved in the homeostatic regulation of blood pressure, as well as sodium and water levels. ANP have been found to vary in length from about 21 to about 126 amino acids with a common structural feature being one or more disulfide-looped sequences of 17 amino acids with various amino- and carboxy-terminal sequences attached to the cysteine moiety. ANP have been found to bind to specific binding sites in various tissues including kidney, adrenal, aorta, and vascular smooth muscle with affinities ranging Hypertension 7, 469 (1985)!. In addition, it is believed that ANP binds to specific receptors in the brain and possibly serves as a neuromodulator as well as a conventional peripheral hormone.
The biological properties of ANP involve potent diuretic
atriuretic and vasodilatory/hypotensive effects as well as an inhibitory effect on renin enkephalinase, the metabolic degradation of the naturally-occurring ANP are inhibited, thereby providing a potent ANP-mediated diuretic, natriuretic, hypotensive, hypoaldosteronemic effects. Inhibition of enkephalinase would therefore be useful in a patient suffering from disease states characterized by abnormalities in fluid, electrolyte, blood pressure, intraocular pressure, renin, or aldosterone homeostasis, such as, but not limited to, hypertension, renal diseases, hyperaldosteronemia, cardiac hypertrophy, glaucoma and congestive heart failure.
In addition, the compounds of the present invention are inhibitors of Angiotensin-Converting Enzyme (ACE). ACE is a peptidyl dipeptidase which catalyzes the conversion of angiotensin I to angiotensin II. Angiotensin II is a vasoconstrictor which also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE would therefore be useful in a patient suffering from disease states such as hypertension and congestive heart
Douglas, "Polypeptides--Angiotensin, Plasma Kinins, and Others", Chapter 27, in Goodman and Gillman's the Pharmacological Basis of Therapeutics, 7th edition, 1985, pp. 652-3, MacMillan Publishing Co., New York, N.Y.!. In addition, it has been discovered that ACE inhibitors are useful
REFERENCES:
patent: 3334091 (1967-08-01), Houlihan
patent: 3334095 (1967-08-01), Houluhan
patent: 4080449 (1978-03-01), Croisier et al.
patent: 4320057 (1982-03-01), Freed et al.
patent: 4391752 (1983-07-01), Crossley
patent: 4399136 (1983-08-01), Hassall et al.
patent: 4415496 (1983-11-01), Harris et al.
patent: 4487929 (1984-12-01), Hassall et al.
patent: 4512924 (1985-04-01), Attwood et al.
patent: 4584294 (1986-04-01), Ruyle
patent: 4658024 (1987-04-01), Attwood et al.
patent: 4692438 (1987-09-01), Hassall et al.
patent: 4716232 (1987-12-01), Ternansky
patent: 4734504 (1988-03-01), Holmes
patent: 4734505 (1988-03-01), Holmes
patent: 4762924 (1988-08-01), Hassall et al.
patent: 4772701 (1988-09-01), Attwood et al.
patent: 4782149 (1988-11-01), Lawton et al.
patent: 4785093 (1988-11-01), Hassall et al.
patent: 4808713 (1989-02-01), Attwood et al.
patent: 4824832 (1989-04-01), Flynn et al.
patent: 4826980 (1989-05-01), Hassall et al.
patent: 4973585 (1990-11-01), Flynn et al.
patent: 5208230 (1993-05-01), Flynn et al.
patent: 5238932 (1993-08-01), Flynn et al.
patent: 5525723 (1996-06-01), Robl
Flynn, et al., J. Am. Chem. Soc. 109, 7914 (1987).
Flynn, et al., Peptide Chemistry (1987); T. Shiba & Sakakibara (ed.), Protein Research Foundation, Osaka (1988).
Flynn, et al., Tetrahedron Letters, vol. 31 (6), 815-88 (1990).
Attwood, et al., J. Chem. Soc. Perkin Trans. I, pp. 1011-1019 (1986).
Natoff, et al., Drugs of the Future, vol. 12 (5): 475-483 (1987).
Powell Jerry S. et al., Journal of American College of Cardiology, vol. 17, No. 6, pp. 137B-142B (May 1991).
Davis, Harry R. et. al., Supplement I Circulation, vol. 86, No. 4, p. I-220 (0873), (Oct. 1992).
W.H. Parsons et al. Biochemical and Biophysical Research Communications vol. 117, No. 1, 1993 (Nov. 30, 1983).
Burkholder, et al. Bioorganic and Medical Chem. Letters, vol. 3, No. 2, pp. 231-234, 1993.
Flynn et al., J. Med. Chem. 1993, 36 2420-2423.
J. Med. Chem. 1992, 35, 823-832, Timothy D. Ocain et al.
Flynn et al. Bioorganic and Medical Chem. Letters, vol. 1, 309, 1991.
Fournie-Zaluski, Marie-Claude et al., J. Med. Chem., 1992 vol. 35, pp. 2473-2481, 1259-1266.
French, John F., Jour. of Pharm and Exper. Therapeutics, vol. 268, No. 1, pp. 180-186, 1994.
Beight Douglas W.
Flynn Gary A.
French John F.
Kehne John H.
Mehdi Shujaath
Hoechst Marion Roussel Inc.
Rao Deepak
Shah Mukund J.
Stemerick David M.
LandOfFree
Mercaptoacetylamide disulfide derivatives useful as inhibitors o does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mercaptoacetylamide disulfide derivatives useful as inhibitors o, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mercaptoacetylamide disulfide derivatives useful as inhibitors o will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-979191